Raymond James Financial Inc. Acquires New Holdings in Genmab A/S (NASDAQ:GMAB)

Raymond James Financial Inc. bought a new stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 118,002 shares of the company's stock, valued at approximately $2,463,000.

Other large investors have also recently added to or reduced their stakes in the company. Two Sigma Advisers LP lifted its position in shares of Genmab A/S by 84.1% during the 3rd quarter. Two Sigma Advisers LP now owns 615,100 shares of the company's stock valued at $14,996,000 after acquiring an additional 280,900 shares during the last quarter. FMR LLC lifted its holdings in shares of Genmab A/S by 13.5% during the third quarter. FMR LLC now owns 278,194 shares of the company's stock valued at $6,782,000 after purchasing an additional 33,076 shares during the last quarter. ABC Arbitrage SA acquired a new position in shares of Genmab A/S in the 4th quarter valued at $3,692,000. AIMZ Investment Advisors LLC purchased a new position in Genmab A/S in the 4th quarter worth about $3,525,000. Finally, Y Intercept Hong Kong Ltd boosted its holdings in shares of Genmab A/S by 371.0% in the fourth quarter. Y Intercept Hong Kong Ltd now owns 73,696 shares of the company's stock worth $1,538,000 after buying an additional 58,048 shares during the period. 7.07% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on GMAB shares. William Blair upgraded shares of Genmab A/S from a "market perform" rating to an "outperform" rating in a research report on Tuesday, March 11th. Sanford C. Bernstein cut Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday. HC Wainwright reissued a "buy" rating and set a $50.00 price target on shares of Genmab A/S in a research report on Thursday, January 23rd. BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. Finally, Leerink Partnrs raised Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $41.33.

Remove Ads

Genmab A/S Stock Up 0.9 %

Shares of GMAB traded up $0.16 during midday trading on Wednesday, reaching $18.82. 1,928,595 shares of the stock were exchanged, compared to its average volume of 970,440. The company has a market cap of $12.45 billion, a price-to-earnings ratio of 10.82, a P/E/G ratio of 2.65 and a beta of 0.98. The firm has a 50 day simple moving average of $20.76 and a 200-day simple moving average of $21.71. Genmab A/S has a 12-month low of $18.48 and a 12-month high of $30.50.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. Research analysts expect that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.